Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DBV Technologies logo — On a mission to advance epicutaneous immunotherapy using our...

DBV Technologies

On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™

Founded 2002 France France 187 employees Post-IPO Equity Total: $239.80M Biopharma, Biotechnology +1

General Information

Company Name DBV Technologies
Founded Year 2002
Location France France
Founders / Decision Makers
Team member
Employees 187
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with DBV Technologies. To contact DBV Technologies, visit dbv-technologies.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DBV Technologies compare?

A PDF of DBV Technologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DBV Technologies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DBV Technologies

DBV Technologies is a global clinical stage biopharmaceutical company founded in 2002 by pediatricians who envisioned the safe and effective treatment of food allergies. The company is headquartered in France and is dedicated to advancing epicutaneous immunotherapy using their innovative technology platform, Viaskin™, in order to address immunologic diseases with significant unmet medical need. DBV Technologies is focused on exploring the use of Viaskin to tackle food allergies and aims to offer the first epicutaneous immunotherapy treatment for peanut allergy, which afflicts millions of patients. Their last investment, a noteworthy €181.00MPost-IPO Equity investment at 09 June 2022, was backed by prominent investors including Bpifrance, RA Capital Management, Vivo Capital, Braidwell, Venrock Healthcare Capital Partners, Fairmount Funds Management, and Baker Brothers Advisors LLC. Their mission to develop treatments for patients and their families drives their commitment to pioneering the potential new class of immunotherapy, impacting patients suffering from inflammatory and autoimmune diseases.

Business keywords: Epicutaneous Immunotherapy, Viaskin Technology, Biopharmaceutical Research, Treatment Development, Immunologic Diseases, Pediatric Allergies, Autoimmune Disease Therapies, Inflammatory Disease Treatments, Clinical Stage Research, Peanut Allergy Treatment, Immunotherapy Innovations

Services & Products

Development and clinical trials of epicutaneous immunotherapy for food allergies and immunological diseases

Target Customers

Patients with food allergies and other immunological diseases healthcare providers investors

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €181.00M 7
Bpifrance RA Capital Management Vivo Capital
Bpifrance, RA Capital Management +5
09 Jun 2022
Series C $25.50M 5
Sofinnova Partners Lundbeckfonden Ventures Alto Invest
Sofinnova Partners, Lundbeckfonden Ventures +3
05 Jan 2011
Venture Round $2.70M -
17 Dec 2010
Series B €6.00M 2
Sofinnova Partners
Sofinnova Partners, ALK Abelló
22 Jan 2009
Venture Round €12.30M 1
Karista
Karista
30 Jan 2006
Venture Round €12.30M 2
Sofinnova Partners Apax Partners
Sofinnova Partners, Apax Partners
23 Jan 2006
Venture Round Undisclosed 1
Omega Funds
Omega Funds
01 Jan 2005

Latest News

View All
Le Journal des biotechs : Hervé Affagard (Maat Pharma), Frédéric Gomez (Pharmium Securities) — Boursorama.com
Le Journal des biotechs : Hervé Affagard (Maat Pharma), Frédéric Gomez (Pharmium Securities)
Boursorama.com Apr 15, 2025

DBV Technologies Alternatives & Competitors

View All Alternatives
DBV Technologies vs
SFA Therapeutics
SFA Therapeutics United States

A New Paradigm in Drug Development

Convertible Note
9 employees
Biotechnology, Health Care
DBV Technologies vs
Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. United States

Leading the Next Evolution of Immunotherapies

Post-IPO Equity
99 employees
Biotechnology, Health Care
DBV Technologies vs
Allakos Inc
Allakos Inc United States

Antibody-based therapeutics to treat various allergies and diseases

Acquired
24 employees
Biopharma, Biotechnology
View all alternatives

FAQ About DBV Technologies

On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™
DBV Technologies was founded in 2002.
DBV Technologies is headquartered in France.
DBV Technologies operates in Biopharma, Biotechnology and Health Care. Its work centres on Epicutaneous Immunotherapy, Viaskin Technology, Biopharmaceutical Research and Treatment Development. Its customers include Patients with food allergies and other immunological diseases, healthcare providers and investors.
DBV Technologies has approximately 187 employees.
DBV Technologies has completed 7 funding rounds, raising a total of $239.80M. The latest funding stage is Post-IPO Equity.
DBV Technologies offers: Development and clinical trials of epicutaneous immunotherapy for food allergies and immunological diseases.
Top alternatives and competitors to DBV Technologies include SFA Therapeutics, Alpine Immune Sciences, Inc., Allakos Inc, ZaBeCor Pharmaceuticals, VBL Therapeutics (Nasdaq:VBLT). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DBV Technologies and SFA Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DBV Technologies, https://bouncewatch.com/company/dbv-technologies, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes